Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord

BMC Infectious Diseases

For the Hepatitis C- working group for COHERE in Eurocoord¹  Jürgen Rockstroh¹  Dorthe Raben¹  Genevieve Chene¹  Jaime Cosin¹  Annelies Zinkernagel¹  Stephane de Wit¹  Josep Mallolas¹  Christina Mussini¹  George Daikos¹  Robert Zangerle¹  Francois Dabis¹  Antonella d’Arminio Montforte¹  Lars Peters¹  Joop Arends¹  Colette Smit¹ 

[1] Stichting HIV Monitoring, Meibergdreef 9, Amsterdam, 1105AZ, The Netherlands

关键词: Abacavir;    HCV treatment response;    HCV treatment;    HCV/HIV co-infection;   

Others  :  1231024
DOI  :  10.1186/s12879-015-1224-1

 received in 2015-03-10, accepted in 2015-10-19,  发布年份 2015

【 摘 要 】

Background

Contradicting results on the effect of abacavir (ABC) on hepatitis C virus (HCV) treatment responses in HIV/HCV co-infected patients have been reported. We evaluated the influence of ABC on the response to pegylated interferon (pegIFN) and ribavirin (RBV)-containing HCV treatment in HIV/HCV co-infected patients in a large European cohort collaboration, including data from different European countries.

Methods

HIV/HCV co-infected patients were included if they were aged ≥16 years, received pegIFN alfa-2a or 2b and RBV combination treatment and were enrolled in the COHERE cohort collaboration. Logistic regression was used to evaluate the impact of abacavir on achieving a sustained virologic response (SVR) to HCV treatment.

Results

In total 1309 HIV/HCV co-infected patients who had received HCV therapy were included, of whom 490 (37 %) had achieved an SVR. No statistically significant difference was seen for patients using ABC-containing regimens compared to patients using an emtricitabine + tenofovir (FTC + TDF)-containing backbone, which was the most frequently used backbone. In the multivariate analyses, patients using a protease inhibitor (PI)-boosted regimen were less likely to achieve an SVR compared to patients using a non-nucleoside reverse-transcriptase inhibitor (NNRTI)-based regimen (OR: 0.61, 95 % CI: 0.41–0.91). The backbone combinations zidovudine&lamivudine (AZT + 3TC) and stavudine&lamivudine (d4t + 3TC) were associated with lower SRV rates (0.45 (0.24–0.82) and 0.46 (0.22–0.96), respectively).

Conclusion

The results of this large European cohort study validate that SVR rates are generally not affected by ABC. Use of d4T or AZT as part of the HIV treatment regimen was associated with a lower likelihood of achieving an SVR.

【 授权许可】

   
2015 Smit et al.

【 参考文献 】

• [1]Bani-Sadr F, Denoeud L, Morand P, Lunel-Fabiani F, Pol S, Cacoub P et al.. Early virologic failure in HIV-coinfected hepatitis C patients treated with the peginterferon-ribavirin combination: does abacavir play a role? J Acquir Immune Defic Syndr. 2007; 45(1):123-125.
• [2]Mira JA, Lopez-Cortes LF, Barreiro P, Tural C, Torres-Tortosa M, de Los SG I et al.. Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother. 2008; 62(6):1365-1373.
• [3]Vispo E, Barreiro P, Pineda JA, Mira JA, Maida I, Martin-Carbonero L et al.. Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 2008; 13(3):429-437.
• [4]Glue P. The clinical pharmacology of ribavirin. Semin Liver Dis. 1999; 19 Suppl 1:17-24.
• [5]Pineda JA, Mira JA, Gil IL, Valera-Bestard B, Rivero A, Merino D et al.. Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients. J Antimicrob Chemother. 2007; 60(6):1347-1354.
• [6]Laufer N, Laguno M, Perez I, Cifuentes C, Murillas J, Vidal F et al.. Abacavir does not influence the rate of virological response in HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther. 2008; 13(7):953-957.
• [7]Amorosa VK, Slim J, Mounzer K, Bruno C, Hoffman-Terry M, Dorey-Stein Z et al.. The influence of abacavir and other antiretroviral agents on virological response to HCV therapy among antiretroviral-treated HIV-infected patients. Antivir Ther. 2010; 15(1):91-99.
• [8]Solas C, Pambrun E, Winnock M, Salmon D, Poizot-Martin I, Dominguez S et al.. Ribavirin and abacavir drug interaction in HIV-HCV coinfected patients: fact or fiction? AIDS. 2012; 26(17):2193-2199.
• [9]Berenguer J, Von Wichmann MA, Quereda C, Miralles P, Mallolas J, Lopez-Aldeguer J et al.. Effect of accompanying antiretroviral drugs on virological response to pegylated interferon and ribavirin in patients co-infected with HIV and hepatitis C virus. J Antimicrob Chemother. 2011; 66(12):2843-2849.
• [10]Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS et al.. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003; 38(2):518-526.
• [11]Hoggard PG, Kewn S, Barry MG, Khoo SH, Back DJ. Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro. Antimicrob Agents Chemother. 1997; 41(6):1231-1236.
• [12]Nunez M, Ocampo A, Aguirrebengoa K, Cervantes M, Pascual A, Echeverria S et al.. Incidence of anaemia and impact on sustained virological response in HIV/HCV-coinfected patients treated with pegylated interferon plus ribavirin. J Viral Hepat. 2008; 15(5):363-369.
• [13]EACS Guidelines version7.02, June 2014. European AIDS Clinical Society. 2014.
• [14]Sulkowski MS, Wasserman R, Brooks L, Ball L, Gish R. Changes in haemoglobin during interferon alpha-2b plus ribavirin combination therapy for chronic hepatitis C virus infection. J Viral Hepat. 2004; 11(3):243-250.
• [15]Rockstroh JK, Peters L, Grint D, Soriano V, Reiss P, Monforte A et al.. Does hepatitis C viremia or genotype predict the risk of mortality in individuals co-infected with HIV? J Hepatol. 2013; 59(2):213-220.
• [16]Opravil M, Rodriguez-Torres M, Rockstroh J, Snoeck E, Chung RT, Tietz A et al.. The dose–response relationship of peginterferon alfa-2a and ribavirin in the treatment of patients coinfected with HIV-HCV. HIV Clin Trials. 2012; 13(1):33-45.
• [17]Sulkowski MS, Shiffman ML, Afdhal NH, Reddy KR, McCone J, Lee WM et al.. Hepatitis C virus treatment-related anemia is associated with higher sustained virologic response rate. Gastroenterology. 2010; 139(5):1602.
• [18]Nunez M, Camino N, Ramos B, Berdun MA, Barreiro P, Losada E et al.. Impact of ribavirin exposure on early virological response to hepatitis C therapy in HIV-infected patients with chronic hepatitis C. Antivir Ther. 2005; 10(5):657-662.
• [19]Soriano V, Puoti M, Sulkowski M, Cargnel A, Benhamou Y, Peters M et al.. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS. 2007; 21(9):1073-1089.
• [20]Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A et al.. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA. 2004; 292(23):2839-2848.
• [21]Smit C, van den Berg C, Geskus R, Berkhout B, Coutinho R, Prins M. Risk of hepatitis-related mortality increased among hepatitis C virus/HIV-coinfected drug users compared with drug users infected only with hepatitis C virus: a 20-year prospective study. J Acquir Immune Defic Syndr. 2008; 47(2):221-225.
• [22]Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T et al.. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 2001; 33(4):562-569.
• [23]Labarga P, Vispo E, Barreiro P, Rodriguez-Novoa S, Pinilla J, Morello J et al.. Rate and predictors of success in the retreatment of chronic hepatitis C virus in HIV/hepatitis C Virus coinfected patients with prior nonresponse or relapse. J Acquir Immune Defic Syndr. 2010; 53(3):364-368.